Caley Castelein Net Worth

The estimated Net Worth of Caley Castelein is at least $3.56 Million dollars as of 10 May 2022. Caley Castelein owns over 1,415,000 units of Aerpio Pharmaceuticals Inc stock worth over $3,400,320 and over the last 8 years Caley sold ARPO stock worth over $164,152.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Caley Castelein ARPO stock SEC Form 4 insiders trading

Caley has made over 2 trades of the Aerpio Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Caley sold 2,345,030 units of ARPO stock worth $164,152 on 19 July 2023.

The largest trade Caley's ever made was selling 2,345,030 units of Aerpio Pharmaceuticals Inc stock on 19 July 2023 worth over $164,152. On average, Caley trades about 144,617 units every 17 days since 2016. As of 10 May 2022 Caley still owns at least 1,545,600 units of Aerpio Pharmaceuticals Inc stock.

You can see the complete history of Caley Castelein stock trades at the bottom of the page.

What's Caley Castelein's mailing address?

Caley's mailing address filed with the SEC is C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER, CO, 80202.

Insiders trading at Aerpio Pharmaceuticals Inc

Over the last 7 years, insiders at Aerpio Pharmaceuticals Inc have traded over $1,836,659 worth of Aerpio Pharmaceuticals Inc stock and bought 3,976,967 units worth $14,245,937 . The most active insiders traders include Muneer A Satter, Advisors Llc Orbi Med Capit..., and Chau Quang Khuong. On average, Aerpio Pharmaceuticals Inc executives and independent directors trade stock every 38 days with the average trade being worth of $486,886. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 8 December 2020, trading 21,400 units of ARPO stock currently worth $41,944.

What does Aerpio Pharmaceuticals Inc do?

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

Complete history of Caley Castelein stock trades at ViewRay and Aerpio Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc executives and stock owners

Aerpio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Bioventures Ltd Novartis Ag...,
  
• Stephen J Hoffman,
  Chief Executive Officer
• Pravin Dugel,
  Director
• Anupam Dalal,
  Director
• Chau Quang Khuong,
  Director
• Steve Pakola,
  Chief Medical Officer
• Cheryl Cohen,
  Director
• Kevin G. Peters,
  See Remarks
• Joseph H. Gardner,
  President
• Michael W Rogers,
  Chief Financial Officer
• Muneer A Satter,
  Director
• Caley Castelein,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Steven Prelack,
  Director
• Regina Marek,
  Vice President of Finance